← Back to Clinical Trials
Recruiting NCT05987774

NCT05987774 Improving Social Communication in Individuals With ASD Using AI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05987774
Status Recruiting
Phase
Sponsor Stanford University
Condition Autism Spectrum Disorder
Study Type INTERVENTIONAL
Enrollment 540 participants
Start Date 2023-10-15
Primary Completion 2027-06-30

Eligibility & Interventions

Sex All sexes
Min Age 11 Years
Max Age 35 Years
Study Type INTERVENTIONAL
Interventions
AI Modules for Improving Social Conversation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 540 participants in total. It began in 2023-10-15 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to identify whether researched and commonly used face-to-face interventions can be effectively implemented through artificial intelligence (AI) using an application on the phone or computer. The investigators plan to recruit verbal individuals diagnosed with autism spectrum disorder who demonstrate challenges with socialization. Modules focusing on various difficulties experienced by autistic individuals will provide practice and feedback using voice recognition and feedback. If effective, this intervention can be scaled up to provide cost-effective accessible assistance to individuals, particularly those who do not have access to care or prefer to secure services in the comfort of their own homes.

Eligibility Criteria

Inclusion Criteria: * Primary diagnosis of autism spectrum disorder (ASD) * Age between 11 to 35 * Ability to engage in social conversation using full sentences for a 20 minute period * Verbal communication difficulties in an individual targeted area (e.g., empathy) as measured on the conversation sample Participants with a co-occuring diagnosis of ADHD, depression, or social anxiety will not be excluded since these are very common in this population and are often related to or a bi-product of difficulties with social conversation. Exclusion Criteria: * Non-documented or self-diagnosis of ASD * At or above 60% correct responding on targeted area of social conversation during conversation probe * No access to phone or computer for intervention sessions * Inability to carry on a conversation during the conversation probe * Apparent intellectual impairment that interferes with the ability to carry on a conversation (e.g., responds only in single words or does not respond to conversation, lack of understanding of questions or content during conversation probe) * Non English speaking * Serious medical or psychiatric issues that may interfere with conversation or the ability to complete the program * Lack of interest in participating.

Contact & Investigator

Central Contact

Lynn K Koegel, PhD

✉ lynnk@stanford.edu

📞 8056899493

Frequently Asked Questions

Who can join the NCT05987774 clinical trial?

This trial is open to participants of all sexes, aged 11 Years or older, up to 35 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05987774 currently recruiting?

Yes, NCT05987774 is actively recruiting participants. Contact the research team at lynnk@stanford.edu for enrollment information.

Where is the NCT05987774 trial being conducted?

This trial is being conducted at Stanford, United States.

Who is sponsoring the NCT05987774 clinical trial?

NCT05987774 is sponsored by Stanford University. The trial plans to enroll 540 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology